Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Simulations Plus, Inc. - Common Stock (NQ:SLP)

13.27 +0.23 (+1.76%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Simulations Plus, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Simulations Plus, Inc. - SLP
From Pomerantz LLP
Via GlobeNewswire
Simulations Plus Invests in Clinical Development Technology Company Nurocor
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Reports Third Quarter Fiscal 2025 Financial Results
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Announces Rescheduling of Third Quarter Fiscal 2025 Earnings Release and Conference Call
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus to Participate in the Citizens Medical Devices and Healthcare Services Forum
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Announces Preliminary Third Quarter Fiscal 2025 Revenue
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Releases ADMET Predictor® 13
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Releases DILIsym® 11
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Supports New FDA Roadmap for Reducing Animal Testing in Preclinical Safety Studies
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Reports Second Quarter Fiscal 2025 Financial Results
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Announces Second Quarter Fiscal Year 2025 Earnings and Conference Call Date
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus to Present at the KeyBanc Capital Markets Virtual Healthcare Investor Forum
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus to Participate in Upcoming Healthcare Investor Conferences
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus and Enabling Technologies Consortium Announce Strategic Collaboration to Advance GastroPlus® Enhancements
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Supported Development of Majority of FDA-Approved Drugs in 2024
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Reports First Quarter Fiscal 2025 Financial Results
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Announces First Quarter Fiscal Year 2025 Earnings and Conference Call Date
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus to Participate in the BTIG Digital Health Forum
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus and the University of Connecticut Receive New FDA Grant to Expand Mechanistic Modeling Approaches for Long-Acting Injectables
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus to Participate in the Stephens Annual Investment Conference
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus and Partners Awarded New FDA Grant to Validate In Vitro-In Vivo Extrapolation Methods for Complex Formulations
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Reports Fourth Quarter and Fiscal 2024 Financial Results
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Announces Fourth Quarter and Fiscal Year 2024 Earnings and Conference Call Date
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus and the University of Southern California Secure NIH Grant to Develop New AI Drug Discovery Offerings
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Optimizes Business Unit Structure to Support Future Growth Following Recent Strategic Acquisitions
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Releases DILIsym® X
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Releases ADMET Predictor® Version 12
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus to Participate in KeyBanc’s 25th Annual Technology Leadership Forum
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Announces New Research Project with the International Collaboration on Cosmetics Safety
From Simulations Plus, Inc.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.